Duloxetine compared with placebo for the treatment of women with mixed urinary incontinence

Neurourology and Urodynamics

Volumn 27, Issue 3, 2008, Pages 212-221

  Bent, Alfred E ^a   Gousse, Angelo E ^b   Hendrix, Susan L ^c   Klutke, Carl G ^d   Monga, Ash K ^e   Yuen, Chui K ^f   Muram, David ^g   Yalcin, Ilker ^g   Bump, Richard C ^g  

^a GREATER BALTIMORE MEDICAL CENTER   (United States)

^b UNIVERSITY OF MIAMI   (United States)

^c WAYNE STATE UNIVERSITY   (United States)

^d WASHINGTON UNIVERSITY   (United States)

^e PRINCESS ANNE HOSPITAL   (United Kingdom)

^f Manitoba Clinic   (Canada)

^g ELI LILLY AND COMPANY   (United States)

Author keywords

Duloxetine; Mixed urinary incontinence; Stress urinary incontinence; Urge urinary incontinence

Indexed keywords

ANTIDEPRESSANT AGENT; DULOXETINE; PLACEBO;

ADULT; AGED; ARTICLE; ASTHMA; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG WITHDRAWAL; FATIGUE; FEMALE; GASTROESOPHAGEAL REFLUX; HUMAN; INSOMNIA; LABORATORY TEST; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NAUSEA; PATIENT CODING; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SIDE EFFECT; STRESS INCONTINENCE; SYMPTOM; TREATMENT OUTCOME; URGE INCONTINENCE; URODYNAMICS; XEROSTOMIA;

ADULT; AGED; AGED, 80 AND OVER; CANADA; DOUBLE-BLIND METHOD; FEMALE; GREAT BRITAIN; HUMANS; MIDDLE AGED; NEUROTRANSMITTER UPTAKE INHIBITORS; PATIENT SATISFACTION; QUALITY OF LIFE; QUESTIONNAIRES; SEVERITY OF ILLNESS INDEX; THIOPHENES; TREATMENT OUTCOME; UNITED STATES; URINARY INCONTINENCE, STRESS; URINARY INCONTINENCE, URGE; URODYNAMICS;

EID: 40849102897     PISSN: 07332467     EISSN: 15206777     Source Type: Journal    
DOI: 10.1002/nau.20471     Document Type: Article

References (28)

1. Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology of lower urinary tract function: report from the standardistion sub-committee of the International Continence Society. Neurourol Urodyn 2002;21:167-78.
2. Hampel C, Wienhold D, Benken N, et al. Definition of overactive bladder and epidemiology of urinary incontinence. Urol 1997;50:4-14.
3. Weidner AC, Myers ER, Visco AG, et al. Which women with stress incontinence require urodynamic evaluation? Am J Obstet Gynecol 2001;184:20-7.
4. Sandvik H, Hunskaar S, Vanvik A, et al. Diagnostic classification of female urinary incontinence: An epidemiological survey corrected for validity. J Clin Epidemiol 1995;48:339-43.
5. Hannestad YS, Rortveit G, Sandvik H, et al. A community-based epidemiological survey of female urinary incontinence-. The Norwegian EPINCONT study. J Clin Epidemiol 2000;53:1150-7.
6. Thor KB, Katofiasc MA. Effects of duloxetine, a combined serotonin and norepinephrine reuptake inhibitor, on central neural control of lower urinary tract function in the chloralose-anesthetized female cat. J Pharmacol Exp Ther 1995;274:1014-24.
7. Cardozo L, Drutz HP, Baygani SK, et al. Pharmacological treatment of women awaiting surgery for stress urinary incontinence. Obstet Gynecol 2004;104:511-9.
8. Dmochowski RR, Miklos JR, Norton PA, et al. Duloxetine versus placebo in the treatment of North American women with stress urinary incontinence. J Urol 2003a;170:1259-63.
9. Ghoneim GM, Van Leeuwen JS, Elser DM, et al. A randomized controlled trial of duloxetine alone, pelvic floor muscle training alone, combined treatment, and no treatment in women with stress urinary incontinence. J Urol 2005;173:1647-53.
10. Millard RJ, Moore K, Rencken R, et al. Duloxetine versus placebo in the treatment of stress urinary incontinence: A four continent randomized clinical trial. Br J Urol Int 2004;93:311-8.
11. Norton PA, Zinner NR, Yalcin I, et al. Duloxetine versus placebo in the treatment of stress urinary incontinence. Am J Obstet Gynecol 2002;187:40-8.
12. Van Kerrebroeck P, Abrams P, Lange R, et al. Duloxetine versus placebo in the treatment of European and Canadian women with stress urinary incontinence. Br J Obstet Gynaecol 2004;111:249-57.
13. Steers WD, Herschorn S, Kreder KJ, et al. Duloxetine compared with placebo for the treatment of women with symptoms of overactive bladder. Br J Urol 2007; in press. Published online. DOI: 10.1111/j.1464-410X.2007.06980.x
14. Bent AE, Gousse AE, Hendrix SL, et al. Validation of a two-item quantitative questionnaire for the triage of women with urinary incontinence. Obstet Gynecol 2005;106:767-73.
15. Avery K, Donovan J, Peters TJ, et al. ICIQ: A brief and robust measure for evaluating the symptoms and impact of urinary incontinence. Neurourol Urodyn 2004;23:322-30.
16. Wagner TH, Patrick DL, Bavendam TG, et al. Quality of life of persons with urinary incontinence: Development of a new measure. Urology 1996;47:67-71.
17. Patrick DL, Martin ML, Bushnell DM, et al. Quality of life of women with urinary incontinence: Further development of the Incontinence Quality of Life Instrument (I-QOL) (published erratum appears in Urology 53:1072). Urology 1999;53:71-6.
18. Yalcin I, Bump RC. Validation of two global impression questionnaires for incontinence. Am J Obstet Gynecol 2003;189:98-101.
19. Yalcin I, Bump RC. The effect of prior treatment experience and incontinence severity on the placebo response of stress urinary incontinence. Am J Obstet Gynecol 2004;191:194-7.
20. Dmochowski RR, Davila GW, Zinner NR, et al. Efficacy and safety of transdermal oxybutynin in patients with urge and mixed urinary incontinence. J Urol 2002;168:580-6.
21. Dmochowski RR, Sand PK, Zinner NR, et al. Comparative efficacy and safety of transdermal oxybutynin and oral tolterodine versus placebo in previously treated patients with urge and mixed urinary incontinence. Urol 2003b;62:237-42.
22. Kreder KJ, Jr., Brubaker L, Mainprize T. Tolterodine is equally effective in patients with mixed incontinence and those with urge incontinence alone. Br J Urol Int 2003;92:418-21.
23. Khullar V, Hill S, Laval K-U, et al. Treatment of urge-predominant mixed urinary incontinence with tolterodine extended release: A randomized, placebo-controlled trial. Urol 2004;64:269-75.
24. Kelleher C, Cardozo L. Solifenacin: As effective in mixed urinary incontinence as in urge urinary incontinence. Int Urogynecol J 2006;17:382-8.
25. Staskin DR, Te AE. Short- and long-term efficacy of solifenacin treatment in patients with symptoms of mixed urinary incontinence. Br J Urol Int 2006;97:1256-61.
26. Michel MC, de la Rosette JJMCH, Piro M, et al. Does concomitant stress incontinence alter the efficacy of tolterodine in patients with overactive bladder. J Urol 2004;172:601-4.
27. Castro-Diaz D, Palma PCR, Bouchard C, et al. Effect of dose escalation on the tolerability and efficacy of duloxetine in the treatment of women with stress urinary incontinence. Int J Urogynecol 2007; in press [2006 Dec 12; Epub ahead of print].
28. Hurley DJ, Turner CL, Yalcin I, et al. Duloxetine for the treatment of stress urinary incontinence: An integrated analysis of safety. Eur J Obstet Gynecol Reprod Biol 2006;125:120-8.